Home›Trial›NCT03732794
NCT03732794NAACTIVE NOT RECRUITING

AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

Study Summary

The primary objective of this study is to evaluate the safety and effectiveness of the AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with Left Atrial Appendage (LAA) exclusion using the AtriClip device.

Conditions
Atrial Fibrillation (AF)Persistent Atrial FibrillationLongstanding Persistent Atrial Fibrillation
Interventions / Drugs
AtriCure CryoICE & AtriClip LAA Exclusion
View on ClinicalTrials.gov ↗
Sponsor
ATRC
AtriCure Inc
Cardiac Surgery
D36/100
Study Details
Enrollment150 participants
Primary Completion—
Lead SponsorAtriCure, Inc.
Data Retrieved2026-04-11 02:55:07.545253+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

This trial phase represents an early or specialized stage of clinical development.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 150 participants
Sponsor Catalyst Profile

AtriCure Inc (ATRC) is the sponsoring company for this trial. BiotechSign currently grades this company D (36/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ATRC Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.